Trastuzumab botidotin is under clinical development by KLUS Pharma and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Trastuzumab botidotin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Trastuzumab botidotin overview

Trastuzumab botidotin A-166 is under development for the treatment of advanced, recurrent or metastatic non-small cell lung cancer, relapsed and refractory solid tumor, metastatic colorectal cancer, HER2- positive and HER2 low expressing metastatic breast cancer, recurrent or metastatic non-small cell lung cancer, colorectal cancer and metastatic gastric cancer and adenocarcinoma of gastroesophageal junction. It is administered through parenteral and intravenous route. The drug candidate is a recombinant humanized IgG1 anti-HER2 monoclonal antibody conjugated to duostatin-5. It acts by targeting cells expressing human epidermal growth factor receptor 2 (HER2) and has conjugated with monomethyl auristatin E (MMAE) as a payload. It was also under development for recurrent, or metastatic urothelial carcinoma.

KLUS Pharma overview

KLUS Pharma is a subsidiary of Sichuan Kelun Pharmaceutical Co Ltd, discovers and develops innovative biotherapeutics. The company provides medication for patients suffering from cardiovascular disease, cancer, autoimmune disease, and other severe disorders due to the lack of effective treatment options. KLUS Pharma is headquartered in Cranbury, New Jersey, the US.

For a complete picture of Trastuzumab botidotin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.